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Abstract   13 
Purpose of review. The aim of the present manuscript is to provide an overview of the most updated 14 
studies on the prevalence of primary aldosteronism in primary care and to compare these figures with 15 
the actual rate of diagnosis in clinical practice and with the prevalence of PA in specific subgroup of 16 
patients.  17 
Recent findings. Over the last 20 years the clinical spectrum of low renin hypertension and primary 18 
aldosteronism has changed dramatically. Once considered only in the presence of severe hypertension 19 
and hypokalemia, it is now well known that PA is not uncommon even in patients with mild forms of 20 
hypertension and/or normokalaemia. Moreover, recent evidence points towards a large proportion of 21 
normotensive subjects as being affected by subclinical PA, which represents a strong risk factor for 1 
incident hypertension. Moreover, PA patients are exposed to an increased risk of cardio- and cerebro-2 
vascular events and metabolic comorbidities compared with patients affected by essential 3 
hypertension. Disappointingly, primary aldosteronism remains a largely underdiagnosed and under-4 
treated disorder. 5 
Summary. These recent findings further highlight the importance of widening the spectrum of patients 6 
who should be screened for PA, to reduce the cardiovascular risk associated with this medical 7 
condition. 8 
Key words: aldosterone, primary aldosteronism, aldosterone producing adenoma, bilateral adrenal 9 
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Introduction 11 
The 2016 Lancet commission on hypertension highlighted that missing a diagnosis of secondary 12 
hypertension is one of the most important reasons for the unacceptably low control rate of blood 13 
pressure levels in patients with hypertension [1]. Although the 2016 Endocrine Society (ES) guideline 14 
suggests screening for primary aldosteronism (PA) all patients with hypertension and high risk of PA, 15 
[2**], which account for more than half of the hypertensive population, the diagnosis of PA is still 16 
largely inadequate [3*]. 17 
Recently, the PATO (primary aldosteronism in Torino) study reported a PA prevalence of about 6% 18 
in a large cohort of unselected patients with hypertension referred by general practitioners (GPs). PA 19 
prevalence increased with the severity of hypertension, but notably 44% of the identified cases were 20 
affected by stage I hypertension (that is systolic blood pressure level comprised between 140-160 21 
mmHg and/or diastolic levels comprised between 90-100 mmHg) [4*]. These data are particularly 22 
relevant for the observed significant association between PA and a higher risk of cerebro- and cardio-23 
vascular events, cardiac organ damage and metabolic comorbidities compared with patients with 1 
essential hypertension, independent of blood pressure levels [5*]. In fact, the identification of patients 2 
with PA and a correct subtype diagnosis are important to offer a prompt and specific treatment 3 
(surgical cure or targeted pharmacotherapy) which has been demonstrated not only to significantly 4 
improve blood pressure and correct electrolyte abnormalities [6*,7**], but even to revert target organ 5 
damage [8,9] and reduce the cardiovascular associated risk [7**].  6 
Prevalence of primary aldosteronism among patients with hypertension 7 
Over the last 25 years many studies investigated the prevalence of PA in primary care settings and in 8 
referral centres. Although diagnostic criteria varied widely between different studies, especially in 9 
those performed before the publication of the first ES Guideline in 2008 [10], a median PA prevalence 10 
of around 6% in primary care setting and 11% in referral centres is observed [11]. 11 
Prevalence of PA in primary care progressively increases with the severity of hypertension, from 2-12 
4% in mildest forms to 12-13% in the most severe forms, [4*,12] and from 7% in mildest forms to 13 
19% in the most severe in referral centres [13]. In patients with resistant hypertension, PA reaches its 14 
highest prevalence (up to 20%) [14]. 15 
A correct subtype diagnosis allows the identification of an aldosterone producing adenoma (APA) in 16 
one third of PA cases and bilateral adrenal hyperplasia (BAH) in the remaining patients [4*,15]. 17 
Hypokalaemia, once considered a prerequisite to screen for PA, is observed in only 25-40% of 18 
patients with confirmed PA [4*,11,15], and more frequently in patients with resistant hypertension 19 
(45-70%) [16]. 20 
PA seems to be more prevalent in some specific subgroups, such as patients with hypertension and 21 
obstructive sleep apnoea syndrome (OSAS) [17]: for this reason, the 2016 Guideline recommends 22 
that PA screening should be extended also to this category of patients [2*].  23 
The association between PA and a higher risk of developing type 2 diabetes was historically described 1 
by Jerome Conn [18] and recently confirmed in a cross-sectional metanalysis [5*]. However, it is not 2 
yet established if patients with type 2 diabetes should be systematically screened for PA or only 3 
patients with concomitant severe hypertension, in which a high prevalence was observed [19]. 4 
Finally, patients with PA have a higher risk of atrial fibrillation (AF) [5*]. No prospective studies 5 
have investigated the prevalence of PA in patients with AF; an ongoing study in patients with lone 6 
AF will provide more information in the near future [20]. 7 
Prevalence of primary aldosteronism and adrenalectomy in hospital registries 8 
Although widely recognised as the most common cause of secondary hypertension, PA is still largely 9 
underdiagnosed. A recent survey performed among GPs from Italy and Germany, showed that ES 10 
Guidelines are only partially known and applied in clinical practice [3*]. Renin and aldosterone 11 
measurements were requested by GPs in only 7-8% of patients with hypertension [3*], in contrast 12 
with the 50% recommended by the 2016 ES Guideline [2**] and potassium levels were measured by 13 
only 43% of the GPs in Italy and 58% in Germany at diagnosis of hypertension [3*]. PA prevalence 14 
reported in patients with hypertension was 2% from German GPs and 1% from Italian GPs. 15 
Noteworthy, 36% of GPs in Italy have no patients with PA [3*]. 16 
The direct consequence of a poor knowledge and application of international guidelines is the low 17 
prevalence of PA reported by hospital registries worldwide.  18 
If the prevalence of PA is 5% and a prevalence of hypertension among adults is 20-30%, the 19 
prevalence of PA should be 1-1.5% in the general population. However, recent analysis performed in 20 
Italy and Island showed an estimated prevalence of PA from hospital registry between 1.0-2.2/10,000 21 
individuals [21-22]. Patients with a diagnosis of PA in an ambulatory setting and who did not undergo 22 
a subtype diagnosis with adrenal venous sampling or those who had a surgical adrenalectomy are 23 
probably missed by this kind of registries. Nevertheless, even if we consider that patients with milder 1 
PA are probably missed, the figures reported are much lower than expected.  2 
Hypokalaemia was present in 53-100% of patients with PA recorded in European hospital registries 3 
[22-24] and this probably reflects a selection for the most severe cases of PA and a low rate of 4 
diagnosis of milder forms. A national survey performed in Japan in 2014 demonstrated unilateral 5 
forms of PA in more than two thirds of cases [25]. Since it is known that patients with APAs display 6 
a more severe phenotype compared to patients with BAH [4*], it is probable that even in Asia, milder 7 
forms of PA are largely underdiagnosed.  8 
Since one third of patients with PA have a unilateral form, which benefit from unilateral 9 
adrenalectomy [6*], if we consider that 1-2% of individuals in general population have a new 10 
diagnosis of hypertension each year, we would expect that the number of adrenalectomies should be 11 
2-4/10,000 patients/year. However, the number of adrenalectomies performed for PA in an Italian 12 
Hospital registry was much lower (1.0% of expected adrenalectomies in the period 2000-2015 in the 13 
Italian region of Emilia Romagna).  14 
Prevalence of primary aldosteronism among individuals without hypertension 15 
Only few studies have evaluated the PA prevalence among individuals with normal blood pressure 16 
levels. The first case of PA with normotension and hypokalaemia was described in 1972 in a patient 17 
with aldosterone-producing carcinoma; subsequently, almost 30 cases of PA diagnosed in patients 18 
without hypertension have been reported in the scientific literature [26]. Hypokalaemia was the 19 
hallmark of all cases and most patients were symptomatic, female and relatively young, suggesting 20 
that age and sex may play a protective role in the hemodynamic effects mediated by aldosterone 21 
excess [27]. 22 
In 2011, Ito et al. [28] screened for PA in 44 patients with pre-hypertension and normal potassium 1 
serum level, demonstrating a relatively high prevalence of PA (6.8%). Two of the three patients with 2 
confirmed PA showed a unilateral form of PA and after unilateral adrenalectomy displayed a 3 
reduction of blood pressure levels. A recent study observed a lower prevalence of PA (1.8%) [29]. 4 
However, only 17% of patients with a positive screening test underwent a confirmatory test, 5 
suggesting that the real PA prevalence was likely higher than reported.  6 
Other studies investigated the prevalence of aldosterone overproduction, beyond the strict criteria of 7 
PA diagnosis, identifying a prevalence of 13-14% of patients with unsuppressible aldosterone 8 
secretion [30,31]. Markou et al. used, as confirmatory test, a slightly modified version of the 9 
fludrocortisone suppression test (FST), with different cut-off criteria compared to the ES Guideline  10 
[2*] and with administration of oral dexamethasone to reduce the effect of ACTH on aldosterone 11 
secretion [30]. Instead, Baudrand et al., performed the oral sodium loading test in all patients with 12 
low plasma renin activity (PRA) levels, independent of a positive ARR at basal values [31]. 13 
Although genetic forms of PA are usually associated with a severe phenotype, in some kindreds with 14 
familial hyperaldosteronism patients with the diagnosis of PA and normotension have been reported 15 
[32-35]. 16 
Renin-independent and subclinical aldosteronism  17 
Recent developments on the pathophysiology and molecular basis of aldosterone overproduction and 18 
the study of the subclinical phase of autonomous aldosterone production, allowed the broadening of 19 
the spectrum of low-renin conditions. 20 
Brown et al. [36*], in a prospective longitudinal study, recently demonstrated that individuals with 21 
normal blood pressure levels and suppressed renin activity, display a higher risk of developing 22 
hypertension. Furthermore, only in subjects with suppressed renin, high aldosterone levels were 23 
associated with a higher risk of incident hypertension [36*]. These data are in agreement with the 1 
analysis of the Framingham Offspring Study that demonstrated an association between aldosterone 2 
levels and the development of hypertension in patients with normal blood pressure levels [37,38]. 3 
The progressive increase of aldosterone secretion, until its production becomes independent of renin 4 
regulation, results in normotensive aldosteronism. Patients with normotensive aldosteronism display 5 
a >15 fold higher risk of developing hypertension than controls without PA [30]. 6 
Aldosterone levels are not detrimental per se: in a context of sodium deficiency, high aldosterone 7 
levels are part of a homeostatic balance and do not increase the risk of aldosterone-associated 8 
cardiovascular damage. On the other hand, high aldosterone levels in the presence of high salt-diet 9 
are inappropriate and not “homeostatic”, leading to higher incidence of hypertension and 10 
cardiovascular damage [5*,39]. 11 
In this context a potential significant role may be played by endogenous ouabain (EO). EO is a 12 
hormone secreted by the adrenal cortex under the regulation of adrenocortical tropic hormone 13 
(ACTH), angiotensin-II (via angiotensin receptor type 2) and sodium loading [40-42]. EO induces 14 
vasoconstriction with consequent increase of vascular resistance and blood pressure levels, and 15 
increases natriuresis [43]. When aldosterone levels are appropriately high, such as in conditions of 16 
sodium deficiency, sodium balance is preserved and EO is not increased. By contrast, when 17 
aldosterone is inappropriately high, the excessive sodium retention causes an increase of EO secretion 18 
by adrenal cortex with consequent further increase in blood pressure levels [39]. These observations 19 
explain the different predictive role of aldosterone levels observed in the study of Brown et al. In a 20 
condition of renin-independent aldosteronism the homeostatic balance is lost and the sodium load is 21 
excessive, leading to increase of EO with consequent development of hypertension. This is not the 22 
case for condition in which aldosterone is physiologically regulated by the renin-angiotensin system. 23 
The recent description of the aldosterone-producing cell clusters (APCCs) provided a potential basis 1 
for the renin-independent aldosterone production. APCCs are clusters of subcapsular zona 2 
glomerulosa-like cells and inner zona fasciculata-like cells of 0.2-1.5 mm of diameter which express 3 
CYP11B2 (aldosterone synthase), but not CYP11B1 (11β-hydroxylase, involved in the last step of 4 
cortisol synthesis) [44,45].   5 
Recent studies demonstrated that APCCs are relatively frequent even in the adrenal glands removed 6 
from patients with normal blood pressure levels [46]. In particular, aging is associated with a decrease 7 
in CYP11B2 expression in the normal zona glomerulosa and concomitant increase in APCCs, 8 
explaining the common finding of a progressive reduction of renin level with age and relative increase 9 
of aldosterone levels [47**]. Some APCCs harbour the same mutations associated with autonomous 10 
aldosterone production in APAs [48-50], suggesting that they could be considered as precursors of 11 
some types of APAs [51].  12 
Conclusions 13 
Patients with a unilateral form of PA treated with laparoscopic adrenalectomy, show a normalization 14 
or significant reduction of blood pressure levels in 84% of cases and 94% having complete 15 
biochemical cure [6*]. Patients with an absent or partial clinical response had a duration of 16 
hypertension significantly longer than cured patients [6*]. Patients with PA are at higher risk of 17 
developing cardiovascular complication and metabolic disturbances compared with patients with 18 
essential hypertension [5*]. These observations underline the importance of an early diagnosis and 19 
treatment of PA. The high prevalence of this condition, even in the general hypertensive population 20 
and in patients with a mild hypertensive phenotype, point towards the necessity of widening the 21 
number of patients with hypertension that should be screened early for PA. Unfortunately, the vast 22 
majority of patients with PA, and particularly the mildest forms, will remain undiagnosed. Therefore, 23 
although robust data from prospective randomized trials on the most appropriate treatment in patients 24 
with low renin hypertension without a confirmed diagnosis of PA are currently lacking, the use of 1 
specific drugs that block aldosterone effects in those patients could prevent the cardio-metabolic 2 
effects of an excessive aldosterone production and should be considered in the early steps of 3 
pharmacological treatment.  4 
Key points:  5 
• Recent studies reported a prevalence of PA of about 6% among unselected patients with 6 
arterial hypertension, with the highest percentage in patients with the most severe degrees of 7 
hypertension, but with a not negligible rate even in patients with mild hypertension.  8 
• Among Italian and German general practitioners, PA is investigated in less than 20% of the 9 
expected patients according to the recommendations of the ES Guideline. 10 
• Analysis of hospital registries demonstrated unacceptably low rates of diagnosis of PA 11 
compared to the expected prevalence and even lower rates of adrenalectomies compared to 12 
the expected rate of diagnosis of unilateral forms of PA. 13 
• The prevalence of PA among individuals with normal blood pressure levels and 14 
normokalaemia is relatively high and, among individuals with normotension, high aldosterone 15 
levels predict a high risk of developing hypertension, especially in the presence of low renin 16 
levels. 17 
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